Stocks · News reference
Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 at SITC 2026
Compass Therapeutics shared new preclinical data at the SITC 2026 Annual Meeting regarding the mechanism of action for its PD-1 x VEGF-A bispecific antibody, CTX-10726.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Compass Therapeutics Reports Third Quarter 2026 Financial Results
Compass Therapeutics, Inc. reported a loss per share of $0.15 for the third quarter of 2026.
Compass Therapeutics Q3 EPS $(0.15) Misses $(0.13) Estimate
8-K filing — Compass Therapeutics, Inc. (CMPX)
Filed: 2026-11-09 AccNo: 0001171843-26-007256 Size: 267 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Compass Therapeutics To Present Data On Novel Mechanism Of Action For CTX-10726 At 41st Society For Immunotherapy Of Cancer Annual Meeting
Compass Therapeutics Announces Participation in Upcoming Investor Events
Compass Therapeutics, Inc. announced its participation in upcoming investor events scheduled for November 2026.